#1 Clinical Trials Search in Europe

Bgb-15025 Citrate

This article discusses the ongoing clinical trials of BGB-15025 Citrate, a promising drug being studied for the treatment of advanced non-small cell lung cancer (NSCLC). The trials aim to evaluate the effectiveness and safety of BGB-15025 Citrate in combination with other investigational agents and chemotherapy for patients with previously untreated, locally advanced, unresectable, or metastatic NSCLC.

Table of Contents

What is BGB-15025 CITRATE?

BGB-15025 CITRATE is an investigational drug currently being studied for its potential in treating certain types of lung cancer. It is being developed by BeiGene, a pharmaceutical company focused on innovative cancer treatments[1]. As an investigational drug, BGB-15025 CITRATE is still in the testing phase and is not yet approved for general use outside of clinical trials.

What condition does BGB-15025 CITRATE target?

BGB-15025 CITRATE is being studied for the treatment of Non-Small Cell Lung Cancer (NSCLC), specifically in patients with advanced stages of the disease. This includes:

  • Locally advanced NSCLC: Cancer that has spread to nearby tissues or lymph nodes but has not spread to other parts of the body.
  • Unresectable NSCLC: Cancer that cannot be removed completely through surgery.
  • Metastatic NSCLC: Cancer that has spread from the lungs to other parts of the body.
These are serious conditions that often require innovative treatment approaches[1].

Current Clinical Trial Information

BGB-15025 CITRATE is currently being studied in a Phase 2 clinical trial. This trial is part of a larger study called a “master protocol” which is investigating several potential treatments for NSCLC. The specific details of this trial are as follows:

  • Trial Name: “A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer.”
  • Trial Phase: Phase 2
  • Trial Design: Open-label, multi-arm study
  • Main Focus: To assess how well tislelizumab (another investigational drug) works in combination with other investigational agents (like BGB-15025 CITRATE) with or without chemotherapy[1].

How is BGB-15025 CITRATE administered?

According to the trial information, BGB-15025 CITRATE is administered as a film-coated tablet taken orally. The maximum daily dose being studied is 150 mg, with a total maximum dose of 113.4 g over a treatment period of up to 24 months[1]. It’s important to note that these dosages are specific to the clinical trial and may not represent the final recommended dosage if the drug is approved in the future.

Who is eligible for the clinical trial?

The clinical trial has specific criteria for who can participate. Some key eligibility factors include:

  • Patients with confirmed NSCLC (nonsquamous or squamous) that is locally advanced, recurrent, or metastatic
  • No prior systemic treatment for metastatic NSCLC
  • Measurable tumor as defined by specific criteria (RECIST v1.1)
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, which indicates the patient’s ability to perform daily activities
There are also several exclusion criteria, such as having mixed small cell lung cancer or certain genetic mutations[1]. It’s crucial to discuss with a healthcare provider to determine if one might be eligible for this or other clinical trials.

What are the objectives of the study?

The main goals of the study involving BGB-15025 CITRATE are:

  1. To assess how well the combination of tislelizumab and investigational agents (like BGB-15025 CITRATE) work against the cancer
  2. To evaluate the safety and tolerability of these drug combinations
  3. To understand how the drugs interact with the body (pharmacokinetics)
  4. To assess if the body develops an immune response to the drugs
These objectives help researchers determine if BGB-15025 CITRATE, in combination with other treatments, could be an effective and safe option for patients with NSCLC[1].

Potential Benefits and Considerations

While BGB-15025 CITRATE shows promise, it’s important to understand that as an investigational drug, its full benefits and risks are not yet known. Potential benefits could include:

  • A new treatment option for advanced NSCLC
  • Possibility of improved outcomes when combined with other treatments
  • Contribution to the advancement of cancer research
However, participants in clinical trials should also be aware of potential risks and considerations:
  • Unknown side effects
  • The treatment may not be effective for everyone
  • Regular medical visits and tests are required
It’s crucial for patients to discuss all options, including clinical trials, with their healthcare team to make informed decisions about their treatment[1].

Aspect Details
Drug Name BGB-15025 Citrate
Form Film-coated tablet
Condition Studied Advanced Non-Small Cell Lung Cancer (NSCLC)
Trial Phase Phase 2
Main Objective Assess antitumor activity of tislelizumab plus investigational agents (including BGB-15025) with or without chemotherapy
Key Eligibility Criteria Confirmed NSCLC, no prior systemic treatment for metastatic NSCLC, measurable lesions, good performance status
Primary Endpoint Confirmed overall response rate (ORR)
Secondary Endpoints Progression-free survival, duration of response, safety and tolerability, pharmacokinetics, immunogenicity
Maximum Daily Dose 150 mg
Maximum Treatment Period 24 months

FAQ

  • What is BGB-15025 Citrate? BGB-15025 Citrate is an investigational drug being studied for the treatment of advanced non-small cell lung cancer. It is administered as a film-coated tablet and is being tested in combination with other drugs and chemotherapy.
  • What is the main goal of the clinical trial involving BGB-15025 Citrate? The main goal of the clinical trial is to assess the antitumor activity of tislelizumab (another drug) plus investigational agents, including BGB-15025 Citrate, with or without chemotherapy in patients with advanced non-small cell lung cancer.
  • Who is eligible to participate in this clinical trial? Eligible participants include adults with confirmed non-small cell lung cancer that is locally advanced, unresectable, or metastatic. They should not have received prior systemic treatment for metastatic NSCLC and must have measurable lesions and good performance status.
  • What are some of the exclusion criteria for the trial? Participants with mixed small cell lung cancer, known actionable mutations with approved targeted therapies, prior therapy with certain immune checkpoint inhibitors, active leptomeningeal disease, uncontrolled brain metastasis, or active autoimmune diseases are generally excluded from the trial.
  • How is the effectiveness of BGB-15025 Citrate being measured in the trial? The effectiveness is primarily measured by the confirmed overall response rate (ORR) as assessed by investigators. Secondary measures include progression-free survival, duration of response, clinical benefit rate, and disease control rate.

Ongoing Clinical Trials on Bgb-15025 Citrate

  • Study of Tislelizumab, LBL-007, and BGB-15025 in Patients with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Romania Spain

Glossary

  • Non-Small Cell Lung Cancer (NSCLC): A type of lung cancer that is the most common form, accounting for about 80-85% of all lung cancers. It grows and spreads more slowly than small cell lung cancer.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Tislelizumab: An investigational drug being studied in combination with BGB-15025 Citrate for the treatment of NSCLC.
  • PD-L1: A protein found on some cancer cells that helps them evade the immune system. Some cancer treatments target PD-L1 to help the immune system recognize and attack cancer cells.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Overall Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Adverse Events: Unexpected medical problems that happen during treatment with a drug or other therapy.
  • Antidrug Antibodies (ADA): Proteins produced by the immune system that recognize and bind to drugs, potentially affecting their effectiveness or causing side effects.

References

  1. http://clinicaltrials.eu/trial/study-of-tislelizumab-lbl-007-and-bgb-15025-in-patients-with-advanced-non-small-cell-lung-cancer/